



August 5, 2019

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director and
President
(TSE Mothers Code: 4592)
Contact: Yoshihiro Kakutani, Corporate Officer of
Management Administration
(TEL. +81-3-6264-3481)

**Announcement on Receiving Japanese Marketing License for
Regenerative Medicine Products**

SanBio Company Limited (hereafter, “the Company”) has announced that it concluded a basic transaction agreement with Suzuken Co., Ltd. regarding the commercial distribution of regenerative medicine products and also agreed on joint development related to a patient support system*¹. The SanBio Group (the Company and its subsidiary SanBio, Inc.) hereby announces that in late July 2019, it also received a Japanese marketing license for regenerative medicine products from the Tokyo Metropolitan Government as part of post-marketing preparations.

The Company aims to begin manufacture and marketing of regenerative medicine products in Japan by the end of 2020 to transform itself into a pharmaceutical company. We will continue to do our utmost to deliver new medicines to patients at the earliest opportunity.

Note 1: See separate release “Announcement on Conclusion of Basic Agreement for Commercial Distribution of Regenerative Medicines with Suzuken Co., Ltd. and Start of Joint Development Related to Patient Support System.”